Difference between revisions of "Allopurinol (Zyloprim)"
Jump to navigation
Jump to search
m |
|||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 4: | Line 4: | ||
<br>Extravasation: unknown | <br>Extravasation: unknown | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information. |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 10: | Line 10: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | * 1966-08-19: Initial approval |
| − | + | ==Also known as== | |
| + | *'''Brand names:''' Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway | ||
| − | [[Category:Drugs FDA approved in 1966]] | + | ==References== |
| + | *'''FLORENCE:''' Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. Epub 2015 Jul 27. [https://doi.org/10.1093/annonc/mdv317 link to original article] [https://pubmed.ncbi.nlm.nih.gov/26216382/ PubMed] [https://clinicaltrials.gov/study/NCT01724528 NCT01724528] | ||
| + | |||
| + | [[Category:Drugs]] | ||
| + | [[Category:Intravenous medications]] | ||
| + | [[Category:Oral medications]] | ||
| + | |||
| + | [[Category:Xanthine oxidase inhibitors]] | ||
| + | |||
| + | [[Category:FDA approved in 1966]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 23:03, 28 May 2024
General information
Class/mechanism: Xanthine oxidase inhibitor.
Route: PO/IV
Extravasation: unknown
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
No known antineoplastic properties. Used for tumor lysis syndrome treatment/prophylaxis.
History of changes in FDA indication
- 1966-08-19: Initial approval
Also known as
- Brand names: Abloric, Aloprim, Caplenal, Milurit, Zyloprim, Zyloric, Zyoway
References
- FLORENCE: Spina M, Nagy Z, Ribera JM, Federico M, Aurer I, Jordan K, Borsaru G, Pristupa AS, Bosi A, Grosicki S, Glushko NL, Ristic D, Jakucs J, Montesinos P, Mayer J, Rego EM, Baldini S, Scartoni S, Capriati A, Maggi CA, Simonelli C; FLORENCE Study Group. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk. Ann Oncol. 2015 Oct;26(10):2155-61. Epub 2015 Jul 27. link to original article PubMed NCT01724528